Characterization of leukemias with ETV6-ABL1 fusion


Disclosures: CC received honoraria, had consulting/advisory role and had research funded by Sanofi S.A.; SPH had ownership interests in Express Scripts, Amgen, Merck and Pfizer, received honoraria from Jazz Pharmaceuticals, Sigma-Tau and Spectrum Pharmaceuticals; DW had research funded by Novartis and BMS; CGM received honoraria from Amgen and Loxo Oncology and had consulting/advisory role in Incyte and had research funded by Loxo Oncology; STC.UNM (Supporting Technology Transfer and Catalyzing Economic Development at the University of New Mexico) have US patent #8,568,974 (RCH, IC, SPH, CLW). The remaining authors declare no relevant competing financial interests.

Contributions: MZ and JZ were responsible for the conception and design of the study, MZ, AVM, GC, RCH, SLH, IC, OZ, CS, MKi, JuSta, DW, CLW and JZ performed research, MZ, AVM, GC, MS, RCH, KGR, SLH, MLL, MKo, IC, OZ, CS, OS, MJM, CC, MKi, JHFF, AN, KM, OAH, JuSta, JaSta, SPH, DW, CGM, CLW, JaSta, JT and JZ collected, analyzed and interpreted data, MZ, AVM and JZ wrote the manuscript and all authors approved the final manuscript.